By 2030, almost 20% of the population will be 65 or older, with cardiovascular and central nervous system diseases accounting for 40% of all fatalities. Therefore, it is crucial to prioritize efforts in preventing and treating these conditions. Hence, it becomes imperative to prioritize efforts dedicated to the prevention and treatment these complex conditions.
However, our current knowledge regarding these diseases remains limited. To address this gap, the present undertaking aims to employ an integrated approach, leveraging the wealth of genetics, metabolomics, proteomics, and comprehensive epidemiological data available within the UK BioBank. Through multidimensional analyses, we aim to discover new risk factors, identify potential biomarkers, and understand causal relationships for various cardiovascular and central nervous system diseases, including stroke, Parkinson’s disease and Alzheimer’s disease, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, abnormal heart rhythm, congenital heart disease, valvular heart disease, carditis, aortic aneurysm, peripheral artery disease, thromboembolic disease, venous thrombosis, and more.
By meticulously analyzing diverse data sources, we will gain valuable insights into the complexities of these diseases. This research will contribute to developing targeted interventions, improved diagnostics, and enhanced management strategies. Our ultimate goal is to improve cardiovascular and central nervous system health outcomes.
